Navigation Links
CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
Date:2/3/2010

VIENNA, Va., Feb. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE  CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2010 BIO CEO & Investor Conference.  Hosted by the Biotechnology Industry Organization (BIO), the conference will take place February 8-9 at the Waldorf=Astoria in New York.

Mr. Kersten's presentation will be on Tuesday, February 9th, at 1:30 p.m. EST.  The presentation will be webcast live with slides and archived until May 11, 2010.  The webcast can be accessed at http://www.veracast.com/webcasts/bio/ceoinvestor2010/05209268.cfm.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine® is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to treat H1N1 hospitalized patients using its L.E.A.P.S.™ technology platform.  This investigational treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu.  This investigational treatment is currently being tested in a clinical study at Johns Hopkins University.  The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

About The BIO CEO & Investor Conference

Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry.  The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry.  This years' conference will feature corporate presentations from more than 120 companies, workshops featuring leading experts on specific therapeutic and technology topics, plenary and panel sessions on timely business issues and industry trends, many opportunities to schedule one-on-one meetings, as well as numerous networking opportunities.  For more information, visit www.ceo.bio.org.

SOURCE CEL-SCI Corporation

RELATED LINKS
http://www.cel-sci.com

'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
2. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
3. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
6. CEL-SCI Expands H1N1 Flu Virus Work
7. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
8. CEL-SCI Posts New Corporate Presentation to Website
9. CEL-SCI Corporation Releases Letter to Shareholders
10. CEL-SCI Corporation Releases Letter to Shareholders
11. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... value, in millions of US dollars, volume (in units) ... Micro Catheters and Glaucoma Drainage Devices. The report ... each of these market segements, and global corporate-level profiles ...
(Date:12/5/2016)... , Dec. 5, 2016 Special purpose needles ... samples such as fluid and cells from organs or lumps ... shapes, and sizes. The global market for special purpose needles ... population. In terms of revenue, the global special purpose needles ... during the forecast period (2016–2026) and is expected to be ...
(Date:12/5/2016)... RATON, Fla. , Dec. 5, 2016 /PRNewswire-USNewswire/ ... Public Research (the Florida Institute) announced today ... LLC, an Orlando -based company ... The Florida Institute supports new company creation based ... for companies spinning out of Florida-based universities and research ...
Breaking Medicine Technology:
(Date:12/5/2016)... Tacoma, Washington (PRWEB) , ... December 05, 2016 ... ... grand opening of its latest transitional care facility – Avamere Transitional Care ... The 39,936 square foot short-term, post-acute health care center will provide patients recovering ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... with leading global lifestyle design firm kathy ireland® Worldwide for five additional years, ... Worldwide entered into an exclusive licensing agreement three years ago to design and ...
(Date:12/5/2016)... Louis, Missouri (PRWEB) , ... December 05, 2016 ... ... across ethnic, gender, and geographic lines. The goal of Castlewood Treatment Centers has ... disorder treatment accessible to as many people as possible. In that spirit, ...
(Date:12/5/2016)... ... December 05, 2016 , ... Florida Hospital ... Hospital West Florida Region. McGuinness brings experience in executive leadership and clinical practice, ... and leaders. , In her new role, that officially begins December 12, 2016, ...
(Date:12/5/2016)... ... ... Sabah Shah MD, MBA has joined the Retina Group of New York (RGONY) ... James M. Maisel, MD and has been providing tertiary medical and surgical retinal care on ... surpassing expectations amongst her peers. Growing up in a family of doctors, Dr. Shah ...
Breaking Medicine News(10 mins):